A first chemotherapeutic agent and a second chemotherapeutic agent for use in cancer therapy, wherein the second chemotherapeutic agent comprises a biologically active complex having anti-tumour activity, wherein the biologically active complex consists of: a peptide of at least 10 amino acids comprising an alpha-helical structure; and oleic acid or an oleate salt, in a ratio of at least 3 oleic acid or oleate salt molecules per peptide molecule. Either the first or second chemotherapeutic agent for use in cancer therapy, for use in conjunction with the other chemotherapeutic agent, pharmaceutical compositions related thereto, and method of treatment.

A first chemotherapeutic agent and a second chemotherapeutic agent for use in cancer therapy, wherein the second chemotherapeutic agent comprises a biologically active complex having anti-tumour activity, wherein the biologically active complex consists of: a peptide of at least 10 amino acids comprising an alpha-helical structure; and oleic acid or an oleate salt, in a ratio of at least 3 oleic acid or oleate salt molecules per peptide molecule. Either the first or second chemotherapeutic agent for use in cancer therapy, for use in conjunction with the other chemotherapeutic agent, pharmaceutical compositions related thereto, and method of treatment.

A first chemotherapeutic agent and a second chemotherapeutic agent for use in cancer therapy, wherein the second chemotherapeutic agent comprises a biologically active complex having anti-tumour activity, wherein the biologically active complex consists of: a peptide of at least 10 amino acids comprising an alpha-helical structure; and oleic acid or an oleate salt, in a ratio of at least 3 oleic acid or oleate salt molecules per peptide molecule. Either the first or second chemotherapeutic agent for use in cancer therapy, for use in conjunction with the other chemotherapeutic agent, pharmaceutical compositions related thereto, and method of treatment.

Provided herein is technology relating to lipid compositions containing bioactive fatty acids and particularly, but not exclusively, to compositions and methods related to the production and use of structured lipid compositions containing sciadonic and/or pinoleic acid alone or in combination with other bioactive fatty acids including, but not limited to, eicosapentaenoic acid, docosahexaenoic acid, conjugated linoleic acid, and non-β-oxidizable fatty acid analogues such as tetradecylthioacetic acid.

Provided herein is technology relating to lipid compositions containing bioactive fatty acids and particularly, but not exclusively, to compositions and methods related to the production and use of structured lipid compositions containing sciadonic and/or pinoleic acid alone or in combination with other bioactive fatty acids including, but not limited to, eicosapentaenoic acid, docosahexaenoic acid, conjugated linoleic acid, and non-β-oxidizable fatty acid analogues such as tetradecylthioacetic acid.

Provided herein is technology relating to lipid compositions containing bioactive fatty acids and particularly, but not exclusively, to compositions and methods related to the production and use of structured lipid compositions containing sciadonic and/or pinoleic acid alone or in combination with other bioactive fatty acids including, but not limited to, eicosapentaenoic acid, docosahexaenoic acid, conjugated linoleic acid, and non-β-oxidizable fatty acid analogues such as tetradecylthioacetic acid.

A method for using mechanical cartridges for the extraction of highly bioavailable omega-3 containing biomass oils from algal biomass is presented. Cartridges may contain an inner bore with an inlet and outlet, and may be amenable to adjustments in pressure and temperature, thereby permitting solvent-based extraction of algal biomass in which solvent temperature, pressure, retention time and flow rate are controllable.

A method for using mechanical cartridges for the extraction of highly bioavailable omega-3 containing biomass oils from algal biomass is presented. Cartridges may contain an inner bore with an inlet and outlet, and may be amenable to adjustments in pressure and temperature, thereby permitting solvent-based extraction of algal biomass in which solvent temperature, pressure, retention time and flow rate are controllable.

A composition is formulated in a therapeutic amount to maintain and promote hair health and growth in a human in need thereof. The composition may comprise a shelf stable, supercritical CO.sub.2 fluid extracted, enhanced lipidosterolic extract of Serenoa repens (LSESr). The enhanced LSESr may have a ratio of free fatty acids to total fatty acids that is greater than about 80.0% and an enrichment of lauric, myristic, oleic and linoleic acids as free fatty acids to total free fatty acids that is greater than about 82.0%. An enrichment of linoleic and linolenic acids together may be greater than about 3.7%.

A composition is formulated in a therapeutic amount to maintain and promote hair health and growth in a human in need thereof. The composition may comprise a shelf stable, supercritical CO.sub.2 fluid extracted, enhanced lipidosterolic extract of Serenoa repens (LSESr). The enhanced LSESr may have a ratio of free fatty acids to total fatty acids that is greater than about 80.0% and an enrichment of lauric, myristic, oleic and linoleic acids as free fatty acids to total free fatty acids that is greater than about 82.0%. An enrichment of linoleic and linolenic acids together may be greater than about 3.7%.